SG11201706940QA - Chimeric antigen receptor - Google Patents
Chimeric antigen receptorInfo
- Publication number
- SG11201706940QA SG11201706940QA SG11201706940QA SG11201706940QA SG11201706940QA SG 11201706940Q A SG11201706940Q A SG 11201706940QA SG 11201706940Q A SG11201706940Q A SG 11201706940QA SG 11201706940Q A SG11201706940Q A SG 11201706940QA SG 11201706940Q A SG11201706940Q A SG 11201706940QA
- Authority
- SG
- Singapore
- Prior art keywords
- antigen receptor
- chimeric antigen
- chimeric
- receptor
- antigen
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464462—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
- A61K2239/24—Dimerizable CARs; CARs with adapter
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504840.8A GB201504840D0 (en) | 2015-03-23 | 2015-03-23 | Chimeric antigen receptor |
| PCT/GB2016/050795 WO2016151315A1 (en) | 2015-03-23 | 2016-03-22 | Chimeric antigen receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201706940QA true SG11201706940QA (en) | 2017-09-28 |
Family
ID=53052211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706940QA SG11201706940QA (en) | 2015-03-23 | 2016-03-22 | Chimeric antigen receptor |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11058722B2 (en) |
| EP (1) | EP3274366B8 (en) |
| JP (3) | JP6675417B2 (en) |
| KR (1) | KR102174280B1 (en) |
| CN (1) | CN107406518B (en) |
| AU (1) | AU2016238583B2 (en) |
| BR (1) | BR112017018252A2 (en) |
| CA (1) | CA2978852C (en) |
| CL (1) | CL2017002413A1 (en) |
| DK (1) | DK3274366T3 (en) |
| ES (1) | ES2773527T3 (en) |
| GB (1) | GB201504840D0 (en) |
| HU (1) | HUE047929T2 (en) |
| IL (1) | IL254254B (en) |
| MX (1) | MX371384B (en) |
| PL (1) | PL3274366T3 (en) |
| PT (1) | PT3274366T (en) |
| RU (1) | RU2752880C2 (en) |
| SG (1) | SG11201706940QA (en) |
| WO (1) | WO2016151315A1 (en) |
| ZA (1) | ZA201705682B (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| US11885807B2 (en) | 2014-03-05 | 2024-01-30 | Autolus Limited | Method for depleting malignant T-cells |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| DK3143134T3 (en) | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modified, natural killer cells and their uses |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| GB201501936D0 (en) * | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| CN107995913B (en) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | Compositions and methods for reprogramming TCRs using fusion proteins |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| IL302917A (en) | 2016-10-07 | 2023-07-01 | Tcr2 Therapeutics Inc | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| EP3544996A2 (en) | 2016-11-22 | 2019-10-02 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| EP3601537A4 (en) | 2017-03-27 | 2021-01-13 | National University of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| CA3056439A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2018176144A1 (en) * | 2017-03-29 | 2018-10-04 | Sunnybrook Research Institute | Engineered t-cell modulating molecules and methods of using same |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| JP7356354B2 (en) | 2017-05-12 | 2023-10-04 | クリスパー セラピューティクス アクチェンゲゼルシャフト | Materials and methods for the manipulation of cells and their use in immuno-oncology |
| EP3662055A1 (en) * | 2017-08-02 | 2020-06-10 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| EP3704150A1 (en) * | 2017-11-01 | 2020-09-09 | F. Hoffmann-La Roche AG | The compbody - a multivalent target binder |
| GB201801831D0 (en) * | 2018-02-05 | 2018-03-21 | Autolus Ltd | Chimeric receptor |
| EP3790629A1 (en) | 2018-05-11 | 2021-03-17 | CRISPR Therapeutics AG | Methods and compositions for treating cancer |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| AU2019269118A1 (en) | 2018-05-15 | 2020-12-03 | Autolus Limited | Chimeric antigen receptor |
| CN112930186A (en) * | 2018-08-16 | 2021-06-08 | 纪念斯隆-凯特琳癌症中心 | Leucine zipper-based compositions and methods of use |
| CN109265550B (en) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | BCMA antibodies, chimeric antigen receptors and drugs |
| AU2019348975A1 (en) | 2018-09-27 | 2021-03-25 | Autolus Limited | Chimeric antigen receptor |
| KR20210072797A (en) * | 2018-10-05 | 2021-06-17 | 세인트 안나 킨더크렙스포르슝 | Chimeric antigen receptor (CAR) group |
| US20220041718A1 (en) | 2018-10-31 | 2022-02-10 | Autolus Limited | Binding domain |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| AU2020240132A1 (en) | 2019-03-21 | 2021-09-16 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
| US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| GB201919017D0 (en) | 2019-12-20 | 2020-02-05 | Autolus Ltd | Cell |
| CN111234033B (en) * | 2020-01-21 | 2021-05-11 | 南京北恒生物科技有限公司 | Multi-chain chimeric antigen receptors and uses thereof |
| GB202004263D0 (en) | 2020-03-24 | 2020-05-06 | Autolus Ltd | Antibody conjugate |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| GB202006820D0 (en) | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| GB202017649D0 (en) | 2020-11-09 | 2020-12-23 | Autolus Ltd | Polypeptide |
| WO2022204326A1 (en) * | 2021-03-24 | 2022-09-29 | The Regents Of The University Of California | Humanized synthetic notch receptors with augmented transactivation domains and uses thereof |
| GB202115329D0 (en) * | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
| WO2024019961A1 (en) * | 2022-07-18 | 2024-01-25 | Cargo Therapeutics, Inc. | Cd2 recruiting chimeric antigen receptors and fusion proteins |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7081443B2 (en) | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
| WO2010102518A1 (en) * | 2009-03-13 | 2010-09-16 | 北京表源生物技术有限公司 | Polymer of fusion proteins |
| KR101156085B1 (en) * | 2010-01-29 | 2012-06-20 | 국립암센터 | Pentamerized 4-1BB ligand protein and use thereof |
| US10745467B2 (en) * | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
| EP2765193B1 (en) * | 2011-10-07 | 2017-08-09 | Mie University | Chimeric antigen receptor |
| EP3964567A1 (en) * | 2012-05-25 | 2022-03-09 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| AU2013312838B2 (en) * | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| PT3300745T (en) * | 2013-02-15 | 2019-11-27 | Univ California | Chimeric antigen receptor and methods of use thereof |
| CN103145849B (en) | 2013-02-18 | 2014-06-11 | 冯振卿 | Chimeric antigen receptor and use thereof |
| MY178233A (en) * | 2013-12-20 | 2020-10-07 | Hutchinson Fred Cancer Res | Tagged chimeric effector molecules and receptors thereof |
| JP6560235B2 (en) | 2014-01-13 | 2019-08-14 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | Chimeric antigen receptor (CAR) having mutation in Fc spacer region and method of using the same |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
-
2015
- 2015-03-23 GB GBGB1504840.8A patent/GB201504840D0/en not_active Ceased
-
2016
- 2016-03-22 MX MX2017010552A patent/MX371384B/en active IP Right Grant
- 2016-03-22 PL PL16712424T patent/PL3274366T3/en unknown
- 2016-03-22 AU AU2016238583A patent/AU2016238583B2/en active Active
- 2016-03-22 WO PCT/GB2016/050795 patent/WO2016151315A1/en active Application Filing
- 2016-03-22 US US15/560,558 patent/US11058722B2/en active Active
- 2016-03-22 DK DK16712424.7T patent/DK3274366T3/en active
- 2016-03-22 CA CA2978852A patent/CA2978852C/en active Active
- 2016-03-22 SG SG11201706940QA patent/SG11201706940QA/en unknown
- 2016-03-22 ES ES16712424T patent/ES2773527T3/en active Active
- 2016-03-22 PT PT167124247T patent/PT3274366T/en unknown
- 2016-03-22 CN CN201680017370.3A patent/CN107406518B/en active Active
- 2016-03-22 HU HUE16712424A patent/HUE047929T2/en unknown
- 2016-03-22 KR KR1020177030391A patent/KR102174280B1/en active IP Right Grant
- 2016-03-22 BR BR112017018252-1A patent/BR112017018252A2/en active Search and Examination
- 2016-03-22 EP EP16712424.7A patent/EP3274366B8/en active Active
- 2016-03-22 RU RU2017132978A patent/RU2752880C2/en active
- 2016-03-22 JP JP2017549766A patent/JP6675417B2/en active Active
-
2017
- 2017-08-21 ZA ZA2017/05682A patent/ZA201705682B/en unknown
- 2017-08-31 IL IL254254A patent/IL254254B/en active IP Right Grant
- 2017-09-25 CL CL2017002413A patent/CL2017002413A1/en unknown
-
2020
- 2020-01-09 JP JP2020001971A patent/JP2020048588A/en not_active Withdrawn
-
2022
- 2022-12-16 JP JP2022201192A patent/JP2023021396A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254254B (en) | Chimeric antigen receptor | |
| HK1245801B (en) | Bcma chimeric antigen receptors | |
| IL250536A0 (en) | Chimeric antigen receptors | |
| GB201503742D0 (en) | Chimeric antigen receptor | |
| IL251030B (en) | Chimeric antigen receptors | |
| PT3294764T (en) | Chimeric antigen receptor compositions | |
| IL258527A (en) | Anti-cd30 chimeric antigen receptors | |
| SG11201606790XA (en) | Chimeric antigen receptor | |
| IL250202B (en) | Bcma chimeric antigen receptors | |
| EP3256496A4 (en) | Chimeric antigen receptors | |
| GB201617290D0 (en) | Novel chimeric antigen receptors | |
| GB201607968D0 (en) | Chimeric antigen receptor | |
| GB201610512D0 (en) | Chimeric antigen receptor | |
| ZA201906321B (en) | Chimeric antigen receptor | |
| GB201709508D0 (en) | Chimeric antigen receptor | |
| GB201519900D0 (en) | Chimeric antigen receptor | |
| GB201810451D0 (en) | Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof | |
| GB201721421D0 (en) | Chimeric antigen receptor | |
| GB201612844D0 (en) | Chimeric antigen receptor | |
| GB201612533D0 (en) | Chimeric antigen receptor | |
| GB201604387D0 (en) | Chimeric antigen receptor | |
| GB201409761D0 (en) | Chimeric antigen receptor | |
| GB201403481D0 (en) | Chimeric antigen receptor |